Metastatic Prostate Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “Metastatic Prostate Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Metastatic Prostate Cancer: Overview
Metastatic prostate cancer marks an advanced stage of the disease where malignant cells originating in the prostate gland have disseminated to other areas of the body, typically via the bloodstream or lymphatic system. It represents a significant clinical challenge due to its potential to affect vital organs such as bones, lymph nodes, liver, and lungs. This stage of prostate cancer often presents with a distinct set of signs and symptoms. Common manifestations include bone pain, which may manifest as discomfort in the lower back, hips, or ribs, urinary symptoms like difficulty urinating or blood in the urine, erectile dysfunction, fatigue, unintended weight loss, and in severe cases, neurological symptoms such as weakness or numbness due to spinal cord compression by metastatic lesions.
Understanding the causes and pathophysiology of metastatic prostate cancer involves exploring various risk factors and the biological mechanisms underlying disease progression. While the precise etiology remains unclear, risk factors for prostate cancer include advanced age, family history, ethnicity, and genetic predisposition. Prostate cancer typically develops from the glandular cells of the prostate gland and progresses slowly over time. As the disease advances, cancer cells may invade surrounding tissues and eventually spread to distant sites. Metastatic dissemination commonly occurs in bones, as prostate cancer cells have a propensity to colonize the skeletal system, leading to debilitating bone pain and skeletal-related events.
Diagnosing metastatic prostate cancer relies on a combination of clinical evaluation, imaging studies, and pathological examination. Physicians may perform a digital rectal examination (DRE) to assess the prostate gland for abnormalities, alongside blood tests such as the prostate-specific antigen (PSA) test to measure PSA levels, which can indicate prostate cancer. Imaging modalities such as bone scans, CT scans, MRI scans, or PET scans play a crucial role in detecting metastases and assessing disease extent. A definitive diagnosis often involves a biopsy of the prostate gland or metastatic lesions, allowing for histopathological examination to confirm the presence of cancer cells and determine tumor characteristics.
Treatment strategies for metastatic prostate cancer aim to prolong survival, alleviate symptoms, and maintain quality of life. Common therapeutic approaches include hormone therapy, also known as androgen deprivation therapy (ADT), which reduces circulating androgen levels to inhibit cancer cell growth. Chemotherapy may be employed for more aggressive or advanced cases, while radiation therapy can target metastatic lesions to alleviate pain or prevent skeletal complications. Surgical interventions may include prostatectomy or palliative procedures to address specific symptoms. Additionally, novel therapies such as immunotherapy hold promise for enhancing the immune system's ability to recognize and eliminate cancer cells. Comprehensive management of metastatic prostate cancer often involves a multidisciplinary approach, integrating medical oncologists, radiation oncologists, urologists, and supportive care specialists to tailor treatment plans to individual patient needs and optimize outcomes.
""Metastatic Prostate Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Prostate Cancer pipeline landscape is provided which includes the disease overview and Metastatic Prostate Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Prostate Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Metastatic Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic Prostate Cancer Emerging Drugs
The pivotal Phase 3 trial met its primary objective of establishing therapeutic equivalence of TAVT-45 to Zytiga in patients with metastatic castrate-resistant prostate cancer and metastatic high-risk castrate-sensitive prostate cancer, in addition to demonstrating a comparable safety profile.7 The NDA is under preparation. Tavanta is currently evaluating strategic options for this asset, an easy-to-swallow alternative to Zytiga, intended for patients with metastatic prostate cancer who have difficulty swallowing. Currently, the drug is in Phase III stage of its development for the treatment of prostate cancer.
Further product details are provided in the report……..
Metastatic Prostate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Metastatic Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Metastatic Prostate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Prostate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Prostate Cancer drugs.
Metastatic Prostate Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Metastatic Prostate Cancer: Overview
Metastatic prostate cancer marks an advanced stage of the disease where malignant cells originating in the prostate gland have disseminated to other areas of the body, typically via the bloodstream or lymphatic system. It represents a significant clinical challenge due to its potential to affect vital organs such as bones, lymph nodes, liver, and lungs. This stage of prostate cancer often presents with a distinct set of signs and symptoms. Common manifestations include bone pain, which may manifest as discomfort in the lower back, hips, or ribs, urinary symptoms like difficulty urinating or blood in the urine, erectile dysfunction, fatigue, unintended weight loss, and in severe cases, neurological symptoms such as weakness or numbness due to spinal cord compression by metastatic lesions.
Understanding the causes and pathophysiology of metastatic prostate cancer involves exploring various risk factors and the biological mechanisms underlying disease progression. While the precise etiology remains unclear, risk factors for prostate cancer include advanced age, family history, ethnicity, and genetic predisposition. Prostate cancer typically develops from the glandular cells of the prostate gland and progresses slowly over time. As the disease advances, cancer cells may invade surrounding tissues and eventually spread to distant sites. Metastatic dissemination commonly occurs in bones, as prostate cancer cells have a propensity to colonize the skeletal system, leading to debilitating bone pain and skeletal-related events.
Diagnosing metastatic prostate cancer relies on a combination of clinical evaluation, imaging studies, and pathological examination. Physicians may perform a digital rectal examination (DRE) to assess the prostate gland for abnormalities, alongside blood tests such as the prostate-specific antigen (PSA) test to measure PSA levels, which can indicate prostate cancer. Imaging modalities such as bone scans, CT scans, MRI scans, or PET scans play a crucial role in detecting metastases and assessing disease extent. A definitive diagnosis often involves a biopsy of the prostate gland or metastatic lesions, allowing for histopathological examination to confirm the presence of cancer cells and determine tumor characteristics.
Treatment strategies for metastatic prostate cancer aim to prolong survival, alleviate symptoms, and maintain quality of life. Common therapeutic approaches include hormone therapy, also known as androgen deprivation therapy (ADT), which reduces circulating androgen levels to inhibit cancer cell growth. Chemotherapy may be employed for more aggressive or advanced cases, while radiation therapy can target metastatic lesions to alleviate pain or prevent skeletal complications. Surgical interventions may include prostatectomy or palliative procedures to address specific symptoms. Additionally, novel therapies such as immunotherapy hold promise for enhancing the immune system's ability to recognize and eliminate cancer cells. Comprehensive management of metastatic prostate cancer often involves a multidisciplinary approach, integrating medical oncologists, radiation oncologists, urologists, and supportive care specialists to tailor treatment plans to individual patient needs and optimize outcomes.
""Metastatic Prostate Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Prostate Cancer pipeline landscape is provided which includes the disease overview and Metastatic Prostate Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Prostate Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Prostate Cancer.
This segment of the Metastatic Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic Prostate Cancer Emerging Drugs
- TAVT-45: Tavanta Therapeutics
The pivotal Phase 3 trial met its primary objective of establishing therapeutic equivalence of TAVT-45 to Zytiga in patients with metastatic castrate-resistant prostate cancer and metastatic high-risk castrate-sensitive prostate cancer, in addition to demonstrating a comparable safety profile.7 The NDA is under preparation. Tavanta is currently evaluating strategic options for this asset, an easy-to-swallow alternative to Zytiga, intended for patients with metastatic prostate cancer who have difficulty swallowing. Currently, the drug is in Phase III stage of its development for the treatment of prostate cancer.
- Onvansertib: Cardiff Oncology
- ONCT-534: Oncternal Therapeutics
- VIO-01: Valerio Therapeutics
- ORIC-944: ORIC Pharmaceuticals
Further product details are provided in the report……..
Metastatic Prostate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Metastatic Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Metastatic Prostate Cancer
- There are approx. 80+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Tavanta Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Metastatic Prostate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Prostate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Prostate Cancer drugs.
Metastatic Prostate Cancer Report Insights
- Metastatic Prostate Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Metastatic Prostate Cancer drugs?
- How many Metastatic Prostate Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Prostate Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Prostate Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metastatic Prostate Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tavanta Therapeutics
- Cardiff Oncology
- Oncternal Therapeutics
- Valerio Therapeutics
- ORIC Pharmaceuticals
- Telix Pharmaceuticals (Innovations) Pty Limited
- Orion Corporation
- OncoC4, Inc.
- Bristol-Myers Squibb/Ono Pharmaceuticals
- Janssen Research & Development, LLC
- Merck Sharp & Dohme LLC
- Modra Pharmaceuticals
- Minneamrita Therapeutics LLC
- AB Science
- Cellbion Co., Ltd.
- Allarity Therapeutics
- Janssen Research & Development, LLC
- Hansoh BioMedical R&D Company
- Jiangsu HengRui Medicine Co., Ltd.
- Hinova Pharmaceuticals Inc
- ValiRx Plc
- Epizyme, Inc.
- Astrazeneca
- TAVT-45
- Onvansertib
- ONCT-534
- VIO-01
- ORIC-944
- 177Lu-DOTA-rosopatamb
- ODM-209
- ONC-392
- Opevesostat
- Niraparib
- Navarixin
- ModraDoc006/r
- Minnelide 101
- Masitinib
- Lu-177-DGUL
- LiPlaCis
- JNJ-78278343
- JNJ-75229414
- HS-20093
- HRS-5041
- HP518
- Deutenzalutamide
- Nivolumab
- VAL201
- Tazemetostat
- Saruparib
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Metastatic Prostate Cancer: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Metastatic Prostate Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- TAVT-45: Tavanta Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Onvansertib: Cardiff Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- VIO-01: Valerio Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Metastatic Prostate Cancer Key Companies
- Metastatic Prostate Cancer Key Products
- Metastatic Prostate Cancer- Unmet Needs
- Metastatic Prostate Cancer- Market Drivers and Barriers
- Metastatic Prostate Cancer- Future Perspectives and Conclusion
- Metastatic Prostate Cancer Analyst Views
- Metastatic Prostate Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
